Navigation Links
X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
Date:11/1/2010

WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.  The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services.  This grant provides X-BODY with the maximum allowable 50% reimbursement of X-BODY's qualified investment of ~$500,000 in this project.

X-BODY's therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells. There is no selective inhibitor of this targeted pathway on the market. Targeting tumor-initiating cells via this pathway alone or with combination therapy may prevent metastasis in the treatment of non-small cell lung cancer and other solid tumors.  Non-small cell lung cancer is a very common cancer with an 11-14% five-year survival rate and causes ~1.4 million yearly deaths globally.

X-BODY's pre-clinical candidates were discovered using X-BODY's proprietary platform, based on innovative screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.    

About X-BODY BioSciences.

X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA.   Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007.  Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of th
'/>"/>

SOURCE X-BODY BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
2. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
3. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
4. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Cell Biosciences to Acquire Convergent Bioscience
7. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
8. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
9. YM BioSciences reports fiscal year end 2010 operational and financial results
10. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Pipette.com ... include Sartorius/Biohit, Socorex, Capp, and AccuPet brand of ... of 100 uL or less and are a ... forensic applications. , The micropipette promotions were ... and economic alternative products to help customers find ...
(Date:9/17/2014)... global consumption of squalene / squalane is expected to be ... that finds applications in various end user industries such as ... applications like high grade lubrication, and fiber coating additives. ... is regionally segregated. Sophim ( France ), Amyris ... Japan ), SeaDragon Marine Oils Ltd. ( New ...
(Date:9/17/2014)... Ga. , Sept. 17, 2014  MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today the publication of another peer-reviewed clinical study. ... A Multi-center Randomized Controlled Clinical Trial Evaluating ... Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy vs. ...
Breaking Biology Technology:Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... , MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences ... product development company that identifies and advances a diverse ... development, today reported operational and financial results for the ... , "During our first fiscal quarter, we continued to ...
... Nov. 11 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in ... it will,conduct a conference call at 8:00 a.m. Eastern ... its third quarter 2009 financial results. , ...
... Particle Sciences Inc. , a leading pharmaceutical CRO, has ... bringing their total to approximately 21,000 sq ft. "Our ... Dr. Mark Mitchnick, CEO. "2009 has been a record ... the next 12 months. The additional space will be ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results 3Particle Sciences Acquires Additional Space for Operations 2
(Date:9/17/2014)... the Copenhagen Centre for Social Evolution and Yale University ... birth weight and -length can partially predict the likelihood ... autism and schizophrenia later in life. The study analyzed ... hospital diagnoses for up to 30 years, and adjusted ... is published today in the Proceedings of the ...
(Date:9/17/2014)... at UTSouthwestern Medical Center have found that the most ... apoE3, helps repair the lining of blood vessels. Individuals ... benefit of this repair, putting them at higher risk ... identified one mechanism by which apoE3 promotes a healthy ... detrimental," said Dr. Philip Shaul , Professor of ...
(Date:9/17/2014)... complex social behavior by studying nonhuman mammals and primates, ... With their unusually large brains relative to their body ... social environment---not merely in a large population of cooperating ... dynamic setting of alliances and competitors. The same is ... and social carnivores, like hyenas and lions. , A ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2
... and German . Researchers at ... Switzerland have developed a novel method for producing dark-field ... industrial imaging equipment. Dark-field images provide more detail ... diagnose the onset of osteoporosis, breast cancer or Alzheimers ...
... In the January 18th issue of Molecular Cell, Case ... Baker, Ph.D. challenges molecular biologys established body of evidence ... decay. With her collaborator, Ambro van Hoof, Ph.D. of ... tested the faux 3 UTR model and proved it ...
... National Academy of Sciences, Sackler Colloquium series will ... These networks represent the genomic program for the ... types. The meeting will focus on four ... embryonic development; gene networks later developmental processes; regulatory ...
Cached Biology News:New technology sharpens X-ray vision 2Case researcher in RNA biology makes waves by challenging current thinking 2
... Hybrid-Ready Tissues are selected tissues from ... been fixed, embedded in paraffin, sectioned and ... the slides are ready for use in ... The Hybrid-Ready tissue slides are suitable for ...
...
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
Immunochemistry 1 & 2...
Biology Products: